title: The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO trial control arm.
authors.affiliation: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
authors.forename: Yu-Wei
authors.initials: YW
authors.lastname: Chen
authors.affiliation: Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
authors.forename: Alok A
authors.initials: AA
authors.lastname: Khorana
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D035061:Control Groups; D018849:Controlled Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D016016:Proportional Hazards Models; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000208:ethnology* / Q000517:prevention & control; D044469:Racial Groups / Q000706:statistics & numerical data*; D012306:Risk; D019851:Thrombophilia / Q000139:chemically induced / Q000188:drug therapy; D014481:United States / Q000453:epidemiology; D054556:Venous Thromboembolism / Q000139:chemically induced / Q000208:ethnology* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D006495:Heparin, Low-Molecular-Weight; C569346:semuloparin